11 drug(s) with this reaction
3,398 total reports
Insomnia has been reported as an adverse reaction across 11 drug(s) manufactured by Chattem Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 3,398 adverse event reports mention insomnia in connection with Chattem Inc products.
This page provides a breakdown of which Chattem Inc drugs are most commonly associated with insomnia, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Chattem Inc drugs have insomnia listed in their FDA adverse event reports, sorted by report count:
In addition to insomnia, the following adverse reactions have been reported across Chattem Inc's drug portfolio:
11 drug(s) manufactured by Chattem Inc have insomnia listed in their FDA adverse event reports: TRIAMCINOLONE ACETONIDE, LEVOCETIRIZINE DIHYDROCHLORIDE, LIDOCAINE, MENTHOL, FEXOFENADINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE, and others.
There are a combined 3,398 reports of insomnia across 11 Chattem Inc drug(s) in the FDA adverse event database.